InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting

1 October, 2018

InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting.

InteRNA OTS Data Announcement

Please click here to read InteRNA Post er #63 showing the data

Please click here to read InteRNA Poster #114 showing the data

EVENTS

07 October 2021 - 11 October 2021

AACR VIRTUAL INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

25 October 2021 - 28 October 2021

BIO-Europe® Digital

08 November 2021 - 15 November 2021

LSX’s Inv€$tival ShowcaseTM, Online & Physical, London, United Kingdom

16 November 2021 - 19 November 2021

8th China Healthcare Summit, Online & Physical , Shanghai Shi, China

NEWS

1 October, 2018

InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting

18 April, 2018

InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting

27 March, 2018

InteRNA to Present Preclinical Proof-of-Concept Data on Lead microRNA Candidate INT-1B3 at 2018 AACR Annual Meeting

21 February, 2018

New Journal of Neuroscience paper shows that our functional screening platform for miRNA drug candidates works also nicely outside Oncology

28 February, 2017

New Cancer Research paper on the Mode of Action of one of our proprietary miRNA drug candidates for the treatment of epithelial cancers by UMC radboud icw InteRNA Technologies under our STW grant program

1-5 6-10 11-15 16-20 21-25 26-30 31-35 36-40 41-41